Molecular basis for the inhibition of p53 by Mdmx

Cell Cycle

Volumn 6, Issue 19, 2007, Pages 2386-2392

  Popowicz, Grzegorz M ^a   Czarna, Anna ^a   Rothweiler, Ulli ^a   Szwagierczak, Aleksandra ^a   Krajewski, Marcin ^a   Weber, Lutz ^b   Holak, Tad A ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b NexusPharma Inc   (United States)

Author keywords

Cancer; Mdm4; Mdmx; Nutlin; p53; Structure

Indexed keywords

METHIONINE; NUTLIN 3; PROTEIN DERIVATIVE; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; CRYSTAL STRUCTURE; DRUG ACTIVATION; DRUG INHIBITION; HUMAN; HYDROPHOBICITY; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; TUMOR CELL;

EID: 35948933091     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.19.4740     Document Type: Article

References (51)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10.
2. Toledo F, Wahl M. Regulating the p53 pathway: In vitro hypotheses, in vivo veritas. Nat Rev Canc 2006; 6:909-23.
3. Marine JCW, Dyer MA, Jochemsen AG. MDMX: From bench to bedside. J Cell Sci 2007; 120:371-78.
4. Chene P. Inhibiting the p53-MDM2 interaction: An important target for cancer therapy. Nat Rev Cancer 2003; 3:102-9.
5. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2006; 13:23-31.
6. Vousden KH, Lane DP. p53 in health and disease. Nature Rev Mol Cell Biol 2007; 8:275-83.
7. Stommel JM, Wahl GM. A new twist in the feedback loop: Stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle 2005; 4:411-7.
8. Meulmeester E, Pereg Y, Shiloh Y, Jochemsen AG. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation. Cell Cycle 2005; 4:1166-70.
9. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-99.
10. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303.
11. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69:1237-45.
12. Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006; 10:501-14.
13. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362:857-60.
14. Lin J, Chen J, Elenbaas B, Levine AJ. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 1994; 8:1235-46.
15. Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2;-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994; 9:2523-29.
16. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP. Structure of the MDM2 oncoprotein bound tho the p53 tumor supressor transcativation domain. Science 1996; 274:948-53.
17. Schon O, Friedler A, Bycroft M, Freund SMV, Fersht AR. Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol 2002; 323:491-501.
18. Yu GW, Rudiger S, Veprintsev D, Freund S, Fernandez-Fernandez MR, Fersht AR. The central region of HDM2 provides a second binding site for p53. Proc Natl Acad Sci USA 2006; 103:1227-32.
19. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. Keeping p53 in check: Essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 2006; 13:927-34.
20. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, van Ham RC, van der Houven van Oordt W, Hateboer G, van der Eb AJ, Jochemsen AG. MDMX: A novel p53-binding protein with some functional properties of MDM2. EMBO J 1996; 15:5349-57.
21. Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G, Bellefroid E, Marine JC. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA 2006; 103:3232-37.
22. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 2006; 281:33030-35.
23. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Rodriguez-Galindo C, Quarto M, Francoz S, Mendrysa SM, Guy RK, Marine JC, Jochemsen AG, Dyer MA. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444:61-6.
24. Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M, Wahl GM. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 2006; 9:273-85.
25. Wade M, Wong ET, Tang M, Stommel JM, Wahl GM. Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem 2006; 281:33036-44.
26. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 2006; 66:3169-76.
27. Gilkes DM, Chen J. Distinct roles of MDMX in the regulation of p53 response to ribosomal stress. Cell Cycle 2007; 6:151-5.
28. Ghosh M, Weghorst K, Berberich SJ. MdmX inhibits ARF mediated Mdm2 sumoylation. Cell Cycle 2005; 4:604-8.
29. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127:1323-34.
30. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 44:656-60.
31. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445:661-65.
32. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-848.
33. Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, Koblish HK, Cummings MD, LaFrance LV, Milkiewicz KL, Calvo RR, Maguire D, Lattanze J, Franks CF, Zhao S, Ramachandren K, Bylebyl GR, Zhang M, Manthey CL, Petrella EC, Pantoliano MW, Deckman IC, Spurlino JC, Maroney AC, Tomczuk BE, Molloy CJ, Bone RF. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem 2005; 48:909-912.
34. Stoll R, Renner C, Hansen S, Palme S, Klein C, Belling A, Zeslawski W, Kamionka M, Rehm T, Muhlhahn P, Schumacher R, Hesse F, Kaluza B, Voelter W, Engh RA, Holak TA. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 2001; 40:336-44.
35. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Cryst 19934; 26:795-800.
36. CCP4, Collaborative computational project, Number 4. Acta Crystallogr Sect D 1994; 50:760-763.
37. McRee DE. XtalView/Xfit - A versatile program for manipulating atomic coordinates and electron density. J Struc Biol 1999; 125:156-65.
38. Lamzin VS, Wilson KS. Automated refinement of protein models. Acta Crystallogr Sect D 1993; 49:129-49.
39. D'Silva L, Ozdowy P, Krajewski M, Rothweiler U, Singh M, Holak TA. Monitoring the effects of antagonists on protein-protein interactions with NMR spectroscopy. J Am Chem Soc 2005; 127:13220-26.
40. Krajewski M, Ozdowy P, D'Silva L, Rothweiler U, Holak TA. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat Med 2005; 11:1135-36.
41. Böttger A, Böttger V, Garcia Echeverria C, Chene P, Hochkeppel HK, Sampson W, Ang K, Howard SF, Picksley SM, Lane DP. Molecular characterization of the hdm2-p53 interaction. J Mol Biol 1997; 269:744-56.
42. Böttger V, Böttger A, Howard SF, Picksley SM, Chene P, Garcia Echeverria C, Hochkeppel HK, Lane DP. Identification of novel Mdm2 binding peptides by phage display. Oncogene 1996; 13:2141-47.
43. Böttger A, Böttger V, Sparks A, Liu WL, Howard SF, Lane DP. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol 1997; 7:860-9.
44. Böttger V, Böttger A, Garcia-Echeverria C, Ramos YF, van der Eb AJ, Jochemsen AG, Lane DP. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 1999; 18:189-99.
45. Dawson R, Mueller L, Dehner A, Klein C, Kessler H, Buchner J. The N-terminal domain of p53 is natively unfolded. J Mol Biol 2003; 332:1131-41.
46. Schon O, Friedler A, Freund S, Fersht AR. Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes. J Mol Biol 2004; 336:197-202.336:197-202.
47. Weber L. Tetrahydro-isoquinolin-1-ones for the treatment of cancer. International Patent 2006, (PCT/EP2006/002471).
48. Sakurai K, Schubert C, Kahne D. Crystallographic analysis of an 8-mer p53 peptide analogue complexed with MDM2. J Am Chem Soc 2006; 128:11000-1.
49. Fasan R, Dias RL, Moehle K, Zerbe O, Obrecht D, Mittl PR, Robinson JA. Structure-activity studies in a family of beta-hairpin protein epitope mimetic inhibitors of the p53-HDM2 protein-protein interaction. Chembiochem 2006; 7:515-526.
50. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 2007; 26:3473-81.
51. Wunderlich M, Ghosh M, Weghorst K, Berberich SJ. MdmX represses E2F1 transactivation. Cell Cycle 2004; 3:472-8.